Mantle Cell Lymphoma: Updates in the Management of Relapsed/Refractory Disease
Search for other papers by Mazyar Shadman in
Current site
Google Scholar
PubMed
Mantle cell lymphoma remains incurable despite recent treatment advances, and most patients experience relapsed/refractory disease. BTK inhibitors are the preferred choice in the relapsed setting, especially in patients with early relapse. For patients with high-risk features such as TP53 mutation, early referral for CAR T-cell therapy should be considered, even in those with stable disease on a BTK inhibitor. Patients without high-risk features may be monitored and initiate CAR T-cell therapy after clinical disease progression. CAR T-cell therapy is an effective treatment with high rate of complete remissions. For patients who do not achieve a complete remission 3 months after CAR-T therapy, bridging therapy with chemotherapy or targeted therapy agents and referral for allogeneic transplant are recommended.
Disclosures: Dr. Shadman has disclosed receiving consulting fees from AbbVie, Inc., Adaptimmune, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Atara Biotherapeutics, BeiGene, Bristol-Myers Squibb Company, Eli Lilly and Company, Epizyme, Genentech, Inc., Innate Pharma, Kite Pharma, MorphoSys AG, Mustang Bio, Pharmacyclics, Sound Biologics, and TG Therapeutics; and receiving grant/research support from AbbVie, Inc., AstraZeneca Pharmaceuticals LP, Atara Biotherapeutics, BeiGene, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Inc., GenMab, Mustang Bio, Pharmacyclics, Sunesis Pharmaceuticals, Inc., and TG Therapeutics.
© 2019-2024 National Comprehensive Cancer Network